Showing results (271-280 of 771) with videos related to
Sort By:
Pageof 78
Clinical, Cosmetic and Investigational Dermatology|September 8, 2016
Relationship between severity of the local skin reactions and the rate of local skin reaction resolution in patients treated with ingenol mebutate gelShelbi C Jim On, Kim Mark Knudsen, Torsten Skov, et al.Toxicology and Applied Pharmacology|April 15, 2003
Synergistic enhancement of H2O2 production in human epidermoid carcinoma cells by Benzo[a]pyrene and ultraviolet A radiationEileen Q Shyong, Yuhun Lu, Amy Goldstein, et al.Journal of the American Academy of Dermatology|November 26, 2009
Cyclosporine and psoriasis: 2008 National Psoriasis Foundation Consensus ConferenceDavid M Rosmarin, Mark Lebwohl, Boni E Elewski, et al.American Journal of Clinical Dermatology|March 25, 2020
Malignancy Rates in Brodalumab Clinical Studies for PsoriasisAlice Gottlieb, Mark Lebwohl, Clive Liu, et al.Journal of Drugs in Dermatology : JDD|April 10, 2020
Recapture Rate of Brodalumab in Patients With a Lapse in TreatmentMark Lebwohl, Jennifer Cather, April Armstrong, et al.Journal of Drugs in Dermatology : JDD|August 12, 2009
The efficacy of three class I topical synthetic corticosteroids, fluocinonide 0.1% cream, clobetasol 0.05% cream and halobetasol 0.05% cream: a Scholtz-Dumas bioassay comparisonChai Sue Lee, John KooDermatologic Clinics|August 23, 2005
Psychopharmacologic therapies in dermatology: an updateChai Sue Lee, John KooClinics in Dermatology|December 19, 2012
Use of psychotropic drugs in dermatology: unique perspectives of a dermatologist and a psychiatristKelly Kyunghwa Park, John KooCutis|October 17, 2008
A practical review and update on the management of pruritus sine materiaMelanie J Tuerk, John KooJournal of Drugs in Dermatology : JDD|October 19, 2007
Rebound of psoriasis after efalizumab discontinuation, despite being on high-dose cyclosporineZahida Khan Maskatia, John KooPageof 78